Key points
- Revenue increased by 9% to $111.85 million
- Loss after tax widened significantly to $4.62 million
- Underlying EBITDA surged by 338% to $5.30 million
- USA market showed strongest growth with 24% revenue increase
- China market revenue remained flat year-on-year
Full summary
Bubs Australia Ltd reported its financial results for the year ended 30 June 2026, showing a revenue increase of 9% to $111.85 million. However, the loss after tax widened significantly to $4.62 million compared to a profit of $5.54 million in the previous year. The underlying EBITDA surged by 338% to $5.30 million. The USA market was the strongest performer with a 24% revenue increase, while China's revenue remained flat year-on-year. Australia saw a 7% decline in revenue due to reduced brand visibility and supply constraints. The company's gross profit margin decreased to 39.8% from 47.8% in FY25 due to increased logistics and regulatory costs. The Group's financial position remains stable with $9.4 million in cash and cash equivalents and $10.0 million in committed un-drawn bank facilities.
Guidance
FY26 Underlying EBITDA $5.30 million, FY26 Revenue $111.85 million
Outlook
The Directors are confident in securing permanent FDA approval and maintaining the going concern basis of accounting.